| Name | Title | Contact Details |
|---|
MEDICAL EQUIPMENT RESOURCES is a Woodlyn, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Vestara is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SpineFrontier Inc. is a growing medical device company that designs, develops and markets implants and instruments that equip surgeons to perform the least invasive spine surgery. SpineFrontier`s innovative and disruptive technologies and techniques apply the Less Exposure Surgery (LES) philosophy to solve clinical problems and make the surgeries safer for the patient and easier for the surgeon. Surgeries can be done in an outpatient center and patients can be discharged same day with rapid recovery, due to less disruption of normal tissues and less time in surgery. We believe LESS is more. LESS time in treatment and recovery is MORE time in action for our patients and surgeons. SpineFrontier is headquartered in Beverly, Massachusetts. It was founded in 2006, and released its first products in 2008. SpineFrontier is a KICventures portfolio company and the exclusive manufacturer of LESS technologies and instruments for surgeon members practicing in the LESS Institute global outpatient network.
Advanced-SurgicalSy is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
BioSig Technologies, Inc. (NASDAQ: BSGM) is a medical device company that is developing a proprietary biomedical signal processing technology platform to address an unmet technology need in the rapidly growing $4.6+ billion electrophysiology (EP) marketplace. Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP™ System. The PURE EP™System is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings even at undetectable levels (until now) with high accuracy to help identify appropriate catheter ablation targets - areas of tissue to destroy that create a heart rhythm disturbance (arrhythmia). BioSig aims to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias, Atrial Fibrillation and Ventricular Tachycardia. PURE EP™ System is an innovative platform, offering potential benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of the need for repeat procedures. BioSig has partnered with Minnetronix on technology development and has received FDA 510(k) clearance for the PURE EP™ System in August 2018. BioSig Technologies, Inc. is a Nasdaq company: NASDAQ:BSGM.